ADELAIDE, Jan 20 (Bernama-AsiaNet) —
– BiomeBank appoints Mr Chris Hall as Chair, effective 17 January 2022.
– Mr Hall brings over 30 years’ experience and impressive track record of investment management across both public and private markets within APAC.
– BiomeBank’s Series A funding round anticipated to close in early 2022.
– Formal Therapeutic Goods Association (“TGA”) approval of Company’s first-generation microbial therapy anticipated in 2022.
BiomeBank today announces Mr Chris Hall as the new Chair for the clinical stage biotechnology company, having recently served as Chief Investment Officer of Ellerston Capital. Prior to this, Mr Hall served as Managing Director of BlackRock Asset Management (North-Asia Ltd). The appointment is effective as of 17 January 2022.